Johnson & Johnson (JNJ): Price and Financial Metrics

Johnson & Johnson (JNJ)

Today's Latest Price: $143.27 USD

0.42 (0.29%)

Updated Jul 8 4:10pm

Add JNJ to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

JNJ Stock Summary

  • With a market capitalization of $376,694,326,614, Johnson & Johnson has a greater market value than 99.82% of US stocks.
  • Johnson & Johnson's stock had its IPO on January 1, 1986, making it an older stock than 92.91% of US equities in our set.
  • The volatility of Johnson & Johnson's share price is greater than that of merely 1.17% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to JNJ, based on their financial statements, market capitalization, and price volatility, are WMT, V, TSM, BRK.B, and MA.
  • Visit JNJ's SEC page to see the company's official filings. To visit the company's web site, go to
JNJ Daily Price Range
JNJ 52-Week Price Range

JNJ Stock Price Chart Technical Analysis Charts

JNJ Price/Volume Stats

Current price $143.27 52-week high $157.00
Prev. close $142.85 52-week low $109.16
Day low $141.70 Volume 6,257,537
Day high $143.39 Avg. volume 9,442,926
50-day MA $145.59 Dividend yield 2.83%
200-day MA $140.75 Market Cap 377.46B

Johnson & Johnson (JNJ) Company Bio

Johnson & Johnson researches and develops, manufactures, and sells various products in the health-care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. Some of its well-known brands include Tylenol-fever, Listerine-bad breath, Splenda-no-calorie sweetener, Neutrogena-skin care, Pepcid-heartburn, Zyrtec - allergy, Motrin-ibuprofen, Sudafed-allergy, and plenty more. The company was founded in 1885 and is based in New Brunswick, New Jersey.

JNJ Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Johnson & Johnson. To summarize, we found that Johnson & Johnson ranked in the 35th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 41.83%. As for the metrics that stood out in our discounted cash flow analysis of Johnson & Johnson, consider:

  • As a business, JNJ is generating more cash flow than 97.96% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately just 17.18% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • JNJ's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 44.76% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Johnson & Johnson? See ENDP, GSK, PDEX, ZTS, and REGN.

JNJ Latest News Stream

Event/TimeNews Detail
Loading, please wait...

JNJ Latest Social Stream

Loading social stream, please wait...

View Full JNJ Social Stream

Latest JNJ News From Around the Web

Below are the latest news stories about Johnson & Johnson that investors may wish to consider to help them evaluate JNJ as an investment opportunity.

Johnson & Johnson: Excellent Company Tarnished By Scandal

Introduction Johnson & Johnson (JNJ) has long been considered a safe investment. It is not a speculative, high-risk, high-reward type of stock. I would rather call Johnson & Johnson a "set it and forget it" type of investment. You buy the stock and then wait for dividends and capital appreciation...

Maximilian Dorn on Seeking Alpha | July 8, 2020

Nonprofits urge Johnson & Johnson to halt sales of Baby Powder globally

The groups, which include educational institutions such as Emory University and activist groups such as Greenpeace, among others, also want the company to recall existing inventory in North America. Janette Robinson Flint, the executive director of Black Women for Wellness, said in a statement that J&J's choice to continue marketing baby powder in international markets, often to Black and Brown consumers, contradicts a statement it issued in June committing to fighting racial inequality.

Yahoo | July 8, 2020

Potential COVID-19 vaccine not 'single solution' to pandemic, Johnson & Johnson CEO says

U.S. drugmaker Johnson & Johnson aims to begin clinical testing of its COVID-19 vaccine in the coming weeks and produce billions of doses in 2021, chief executive officer Alex Gorsky said on Wednesday, but cautioned that it will take more than one vaccine to rein in the virus. Gorsky said it was a good thing other companies are experimenting with different approaches to vaccines, in part because different vaccines might work better in different groups of people. "I think it's going to take multiple vaccines."

Yahoo | July 8, 2020

Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo | July 8, 2020

Where COVID-19 vaccine trials stand

Dr. Fauci says he expects phase 3 vaccine trials to begin at the end of July. Yahoo Finance's Anjalee Khemlani joins the On the Move panel to discuss where vaccine trials stand.

Yahoo | July 8, 2020

Read More 'JNJ' Stories Here

JNJ Price Returns

1-mo -2.38%
3-mo 2.15%
6-mo 0.08%
1-year 4.15%
3-year 17.13%
5-year 64.97%
YTD -0.47%
2019 16.22%
2018 -5.13%
2017 24.43%
2016 15.33%
2015 1.14%

JNJ Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full JNJ Dividend History

Continue Researching JNJ

Want to see what other sources are saying about Johnson & Johnson's financials and stock price? Try the links below:

Johnson & Johnson (JNJ) Stock Price | Nasdaq
Johnson & Johnson (JNJ) Stock Quote, History and News - Yahoo Finance
Johnson & Johnson (JNJ) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1887 seconds.